Groundbreaking pig heart transplant in a human may help patients awaiting donor hearts

(NewMediaWire) – January 10, 2022 – DALLAS – The University of Maryland School of Medicine and the University of Maryland Medical Center announced today the first successful transplant of a genetically modified pig’s heart into a human. According to reports, the patient, a Maryland man, is doing well following the groundbreaking surgery on Friday, Jan. 7 to save his life.

Porcine (pig) heart transplants aren’t approved by the U.S. Food and Drug Administration, however, the federal agency authorized the surgery in this case for “compassionate use” as no other options remained for the patient, according to the medical team.

This medical breakthrough may help health care professionals solve the organ shortage crisis that leaves thousands each year without life-saving heart transplants. About 20% of patients on the heart transplant waiting list die while waiting to receive a transplant or become too sick to be good candidates for the complex transplant procedure.

In 2019 (most recent data available), the United States recorded the highest number of heart transplants, with 3,552 transplantations performed. As of March 11, 2020, 3,661 people were on the waiting list for a heart transplant, and 52 people were on the waiting list for a heart and lung transplant, according to the American Heart Association’s 2021 Heart Disease and Stroke Statistical Update.

Animal organ transplants, or xenotransplants, are extremely rare and can have significant risks to patients as well as bioethical concerns. Pig hearts have been long been seen as possible for transplantation for the human heart due to many similarities, and pig heart valves are used for humans in many cases.

According to the American Heart Association, the most common reasons for a heart transplant are that one or both ventricles of the heart aren’t functioning properly so that severe heart failure is present. A heart transplant gives a patient the opportunity to have a normal heart with normal blood circulation. If the transplant goes well, heart function and blood flow will be closer to normal, and life-sustaining.

Traditionally, a donor heart is matched to the recipient by blood type and body size. Heart transplant recipients must take medications to prevent their immune system from rejecting the new heart. These medicines are called immunosuppressives because they prevent rejection of the new heart by suppressing the body’s normal immune response to a foreign object but may have side effects, which can include an infection or an increased risk of some cancers.

The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.

Additional Resources:

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

###

For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org